Destabilization of Rb by human papillomavirus E7 is cell cycle dependent: E2-25K is involved in the proteolysis

Virology

Volumn 396, Issue 1, 2010, Pages 118-124

  Oh, Kwang Jin ^a   Kalinina, Anna ^a   Bagchi, Srilata ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Cell cycle regulation; E2 25K; E7; Human papillomavirus (HPV); Proteasomal degradation; Rb; Ubiquitination

Indexed keywords

ALANINE; CYSTEINE; LYSINE; PROTEIN E7; PROTEIN MDM2; RETINOBLASTOMA PROTEIN; UBIQUITIN CONJUGATING ENZYME E2;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVE SITE; FEMALE; HALF LIFE TIME; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; UBIQUITINATION; WART VIRUS;

CELL CYCLE; CELL LINE; HUMANS; ONCOGENE PROTEINS, VIRAL; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; UBIQUITIN; UBIQUITIN-CONJUGATING ENZYMES;

HUMAN PAPILLOMAVIRUS;

EID: 70649102943     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.10.018     Document Type: Article

References (43)

1. Berezutskaya E., Morozov A., Raychaudhuri P., and Bagchi S. Differential regulation of the pocket domains of the retinoblastoma family proteins by the HPV16E7 oncoprotein. Cell Growth Differ. 8 (1997) 1277-1286
2. Binné U.K., Classon M.K., Dick F.A., Wei W., Rape M., Kaelin Jr. W.G., Näär A.M., and Dyson N.J. Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat. Cell. Biol. 9 (2007) 225-232
3. Boyer S.N., Wazer D.E., and Band V. E7 protein of human papillomavirus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56 (1996) 4620-4624
4. Cheng S., Schmidt-Grimminger D.C., Murant T., Broker T.R., and Chow L.T. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev. 9 (1995) 2335-2349
5. Cobrinik D. Pocket proteins and cell cycle control. Oncogene 24 (2005) 2796-2809
6. Coux O., and Goldberg A.L. Enzymes catalyzing ubiquitination and proteolytic processing of the p105 precursor of nuclear factor kappaB1. J. Biol. Chem 273 (1998) 8820-8828
7. Dick F.A., and Dyson N. Three regions of the pRB pocket domain affect its inactivation by human papillomavirus E7 proteins. J. Virol. 76 (2002) 6224-6234
8. Dyson N. The regulation of E2F by pRb-family proteins. Genes Dev. 12 (1998) 2245-2262
9. Dou Q.P., and An B. RB and apoptotic cell death. Front Biosci. 3 (1998) d419-30
10. Flores E.R., Allen-Hoffmann B.L., Lee D., and Lambert P.F. The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J. Virol. 74 (2000) 6622-6631
11. Forastiere A., Koch W., Trotti A., and Sidransky D. Head and neck cancer. N. Engl. J. Med. 345 (2001) 1890-1900
12. Gonen H., Bercovich B., Orian A., Carrano A., Takizawa C., Yamanaka K., Pagano M., Iwai M.K., and Ciechanover A. Identification of the ubiquitin carrier proteins, E2s, involved in signal-induced conjugation and subsequent degradation of IkappaB alpha. J. Biol. Chem. 274 (1999) 14823-14830
13. Gonzalez S.L., Stremlau M., He X., Basile J.R., and Munger K. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus Type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J. Virol. 75 (2001) 7583-7591
14. Helt A.M., and Galloway D.A. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 24 (2003) 159-169
15. Hershko A., and Ciechanover A. The ubiquitin system. Ann. Rev. Biochem. 67 (1998) 427-479
16. Higashitsuji H., Itoh K., Nagao T., Dawson S., Nonoguchi K., Kido T., Mayer R.J., Arii S., and Fujita J. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat. Med. 6 (2000) 96-99
17. Huh K., Zhou X., Hayakawa H., Cho J.Y., Libermann T.A., Jin J., Harper J.W., and Munger K. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J. Virol. 81 (2007) 9737-9747
18. Jentsch S. The ubiquitin-conjugation system. Ann. Rev. Genet. 26 (1992) 179-207
19. Ji P., Jiang H., Rekhtman K., Bloom J., Ichetovkin M., Pagano M., and Zhu L. An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant. Mol. Cell. 16 (2004) 47-58
20. Jones D.L., Thompson D.A., and Münger K. Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology 239 (1997) 97-107
21. Kalejta R.F., Bechtel J.T., and Shenk T. Human cytomegalovirus pp71 stimulates cell cycle progression by inducing the proteasome-dependent degradation of the retinoblastoma family of tumor suppressors. Mol. Cell. Biol. 23 (2003) 1885-1895
22. Kalchman M.A., Graham R.K., Xia G., Koide H.B., Hodgson J.G., Graham K.C., Goldberg Y.P., Gietz R.D., Pickart C.M., and Hayden M.R. Huntington is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J. Biol. Chem. 271 (1996) 19385-19394
23. Kehn K., De Fuente L.C., Strouss K., Berro R., Jiang H., Brady J., Mahieux R., Pumfery A., Bottazzi M.E., and Kashanchi F. The HTLV-1 Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation. Oncogene 24 (2005) 525-540
24. Knight J.S., Sharma N., and Robertson E.S. Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18562-18566
25. Mastrandrea L.D., Kasperek E.M., Niles E.G., and Pickart C.M. Core domain mutation (S86Y) selectively inactivates polyubiquitin chain synthesis catalyzed by E2-25K. Biochemistry 37 (1998) 9784-9792
26. Munger K., Baldwin A., Edwards K.M., Hayakawa H., Nguyen C.L., Owens M., Grace M., and Hug K.W. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 78 (2004) 11451-11460
27. Munakata T., Nakamura M., Liang Y., Li K., and Lemon S.M. Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18159-18164
28. Oh K.J., Kalinina A., Wang J., Nakayama K., Nakayama K.e.i.I., and Bagchi S. The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin1/Skp2 containing E3 ligase. J. Virol. 78 (2004) 5338-5346
29. Oh K.J., Kalinina A., Park N.H., and Bagchi S. Deregulation of eIF4E: 4E-BP1 in differentiated human papillomavirus-containing cells leads to high levels of expression of the E7 oncoprotein. J. Virol. 80 (2006) 7079-7088
30. Pickart C.M. Mechanisms underlying ubiquitination. Ann. Rev. Biochem. 70 (2001) 503-533
31. Psyrri A., and DiMaio D. Human papillomavirus in cervical and head-and-neck cancer. Nat. Clin. Pract. Oncol. 5 (2008) 24-31
32. Reinstein E., Scheffner M., Oren M., Ciechanover A., and Schwartz A. Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene 19 (2000) 5944-5950
33. Reusch M.N., Stubenrauch F., and Laimins L.A. Activation of papillomavirus late gene transcription and genome amplification upon differentiation in semisolid medium is coincident with expression of involucrin and transglutaminase but not keratin-10. J. Virol. 72 (1998) 5016-5024
34. Rodrigo-Brenni M.C., and Morgan D.O. Sequential E2s drive polyubiquitin chain assembly on APC targets. Cell 130 (2007) 127-139
35. Saville M.K., Sparks A., Xirodimas D.P., Wardrop J., Stevenson L.F., Bourdon J.C., Woods Y.L., and Lane D.P. Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. J. Biol. Chem. 279 (2004) 42169-42181
36. Sdek P., Ying H., Chang D.L., Qiu W., Zheng H., Touitou R., Allday M.J., and Xiao Z.X. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol. Cell. 20 (2005) 699-708
37. Song S., and Jung Y.K. Alzheimer's disease meets the ubiquitin-proteasome system. Trends Mol. Med. 10 (2004) 565-570
38. Song S., Kim S.Y., Hong Y.M., Jo D.G., Lee J.Y., Shim S.M., Chung C.W., Seo S.J., Yoo Y.J., Koh J.Y., Lee M.C., Yates A.J., Ichijo H., and Jung Y.K. Essential role of E2-25K/Hip-2 in mediating amyloid-beta neurotoxicity. Mol. Cell. 12 (2003) 553-563
39. Stubenrauch F., and Laimins L.A. Human papillomavirus life cycle: active and latent phases. Semin. Cancer Biol. 9 (1999) 379-386
40. Uchida C., Miwa S., Kitagawa K., Hattori T., Isobe T., Otani S., Oda T., Sugimura H., Kamijo T., Ookawa K., Yasuda H., and Kitagawa M. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J. 24 (2005) 160-169
41. Wang J., Sampath A., Raychaudhuri P., and Bagchi S. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells. Oncogene 20 (2001) 4740-4749
42. Ying H., and Xiao Z.X. Targeting retinoblastoma protein for degradation by proteasomes. Cell. Cycle. 5 (2006) 506-508
43. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. 2 (2002) 342-350